Abstracts

REGIONAL VARIATION IN HBV PREVALENCE IN PEOPLE LIVING WITH HIV IN BOTSWANA

Hepatitis B virus (HBV) chronically affects 296 million people worldwide resulting in approximately 820,000 deaths annually. Human immunodeficiency virus (HIV) co-infection increases the risk of HBV disease progression. This study aimed to determine the burden of active HBV in people with HIV (PWH) in a large population-based cohort of rural and peri-urban communities throughout Botswana.…

A RANDOMIZED TRIAL OF HBV REVACCINATION IN MSM BORN IN THE NEONATAL VACCINATION ERA

Implementation of universal neonatal vaccination program against hepatitis B virus (HBV) has significantly reduced HBV seroprevalence in general population and people living with HIV (PLWH). Optimal strategy of revaccination remains unknown among people whose immunity has waned after neonatal vaccination. This randomized controlled trial investigated the serological responses to three standard- (20-?g) or double-dose (40-?g)…

LOW RATES OF HEPATITIS B VACCINATION AMONG HIV PATIENTS

Hepatitis B is a vaccine-preventable disease. The traditional vaccine series is dosed at 0, 1 and 6 months. We examined 3-dose vaccine regimen completed in a cohort of people with HIV (PWH), since hepatitis B impacts 8-10% of PWH due to the common mode of transmission. This is a multi-site retrospective study. Inclusion criteria were…

HEPATITIS B RNA AND CORE-RELATED ANTIGEN IN HIV-HBV COINFECTION

HBV core related antigen (HBcrAg) and HBV RNA are potential surrogate markers for intrahepatic HBV covalently closed-circular (ccc)DNA. cccDNA persists in infected hepatocytes despite HBV DNA suppression with antivirals. There are limited data on these markers in people with HIV-HBV co-infection on HBV-active antiviral therapy (ART). People with HIV-HBV co-infection naïve to ART were recruited…